Tri-Institutional Therapeutics Discovery Institute

Weill Cornell Medicine neuroscientist Dr. Li Gan is driving toward one of the most coveted medical breakthroughs: an effective treatment for Alzheimer’s disease.

 Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited (Takeda) and Bridge Medicines.

Dr. Carl Nathan, chairman of the Department of Microbiology and Immunology at Weill Cornell Medicine, has been awarded the Sanofi – Institut Pasteur Senior International Scientist Award for Biomedical Research in Microbiology and Infection.

The second annual Dean’s Symposium on Opportunities for Entrepreneurship and Academic Drug Development highlighted the resources available to Weill Cornell Medicine investigators to help them turn their research findings into new treatments and therapies for patients.

Dr. Peter T. Meinke, an accomplished chemist with more than 30 years of industry and academic experience, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI).

The goal of the Dean’s Inaugural Symposium on Opportunities for Entrepreneurship and Academic Drug Development, hosted at Weill Cornell Medicine’s Uris Auditorium, was to highlight the resources available to investigators to help them turn their research findings into new treatments and therapies for patients.

Last spring, veteran pharmaceutical executive and entrepreneur Dr. William Polvino was tapped as CEO of Bridge Medicines, a company established in October 2016 to further the development of drugs nurtured by the Tri-Institutional Therapeutics Discovery Institute. 

The Tri-Institutional Therapeutics Discovery Institute, a partnership between Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda, joins with Deerfield Management and Bay City Capital to create an accelerated path to innovative therapies to treat disease.

The Tri-Institutional Therapeutics Discovery Institute is speeding early-stage drug development through an innovative collaboration between academia and industry.